Impact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease

Clinical Interventions in Aging

Volumn 8, Issue , 2013, Pages 1157-1165

  Zeng, Long Huan ^a   Hu, Yi Xin ^a   Liu, Lin ^a   Zhang, Meng ^a   Cui, Hua ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

blocker 2 agonist combination; blockers; 2 agonists; Cardiac function; Elderly COPD patients; Mortality

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; METOPROLOL; NITRATE; PROCATEROL; SALBUTAMOL; SALMETEROL; SPIRONOLACTONE;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; DRUG EFFICACY; ELDERLY CARE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE LINEAR REGRESSION ANALYSIS; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

CARDIAC FUNCTION; ELDERLY COPD PATIENTS; MORTALITY; Β-BLOCKER; Β-BLOCKERS; Β2-AGONIST COMBINATION; Β2-AGONISTS;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ATRIAL NATRIURETIC FACTOR; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; HEART; HEART FUNCTION TESTS; HUMANS; LINEAR MODELS; MALE; MODELS, THEORETICAL; PROTEIN PRECURSORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; VENTRICULAR FUNCTION, LEFT;

EID: 84884584536     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S49644     Document Type: Article

References (38)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176: 532-555.
2. Hardie JA, Vollmer WM, Buist AS, Bakke P, Mørkve O. Respiratory symptoms and obstructive pulmonary disease in a population aged over 70 years. Respir Med. 2005;99:186-195.
3. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28:523-532.
4. Kitzman DW, Gardin JM, Gottdiener JS, et al. Importance of heart failure with preserved systolic function in patients ≥65 years of age. CHS Research Group. Cardiovascular Health Study. Am J Cardiol. 2001;87:413-419.
5. Iversen KK, Kjaergaard J, Akkan D, et al. Chronic obstructive pulmonary disease in patients admitted with heart failure. J Intern Med. 2008;264:361-369.
6. Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007;49:171-180.
7. Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226-3123.
8. Hawkins NM, Huang Z, Pieper KS, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2009;11:292-298.
9. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009;11: 130-139.
10. Bermingham M, O'Callaghan E, Dawkins I, et al. Are beta2-agonists responsible for increased mortality in heart failure? Eur J Heart Fail. 2011;13:885-891.
11. Newton GE, Azevedo ER, Parker JD. Inotropic and sympathetic responses to the intracoronary infusion of a beta2-receptor agonist: a human in vivo study. Circulation. 1999;99:2402-2407.
12. Wood-Baker R, Cochrane B, Naughton MT. Cardiovascular mortality and morbidity in chronic obstructive pulmonary disease: the impact of bronchodilator treatment. Intern Med J. 2010;40:94-101.
13. Au DH, Udris EM, Fan VS, Curtis JR, McDonell MB, Fihn SD. Risk of mortality and heart failure exacerbations associated with inhaled β-adrenoceptor agonists among patients with known left ventricular systolic dysfunction. Chest. 2003;123:1964-1969.
14. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure: MOCHA investigators. Circulation. 1996;94:2807-2816.
15. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-2442.
16. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;4:CD003566.
17. Jabbour A, Macdonald PS, Keogh AM, et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010;55:1780-1787.
18. Hawkins NM, Jhund PS, Simpson CR, et al. Primary care burden and treatment of patients with heart failure and chronic obstructive pulmonary disease in Scotland. Eur J Heart Fail. 2010;12:17-24.
19. Salisbury AC, Reid KJ, Spertus JA. Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes. Am J Cardiol. 2007;99:636-641.
20. van der Woude HJ, Zaagsma J, Postma DS, Winter TH, van Hulst M, Aalbers R. Detrimental effects of beta-blockers in COPD: a concern for nonselective beta-blockers. Chest. 2005;127:818-824.
21. Egred M, Shaw S, Mohammad B, Waitt P, Rodrigues E. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM. 2005;98:493-497.
22. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Available from: http://www.wma.net/en/30publications/10policies/b3/index.html. Accessed October 29, 2012.
23. Hawkins NM, Wang D, Petrie MC, et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail. 2010;12:557-565.
24. Choucair-Jaafar N, Beetz N, Gilsbach R, et al. Cardiovascular effects of chronic treatment with a beta2-adrenoceptor agonist relieving neuropathic pain in mice. Neuropharmacology. 2011;61:51-60.
25. Ng TM, Munger MA, Lombardi WL, et al. Chronically inhaled salmeterol improves pulmonary function in heart failure. J Cardiovasc Pharmacol. 2002;40:140-145.
26. Rosenberg J, Gustafsson F, Remme WJ, Riegger GA, Hildebrandt PR. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure. Cardiovasc Drugs Ther. 2008;22:305-311.
27. Shahzamani M, Ghanavati A, Froutagheh AN, et al. Carvedilol compared with metoprolol on left ventricular ejection fraction after coronary artery bypass graft. J Perianesth Nurs. 2011;26:384-387.
28. Au DH, Bryson CL, Fan VS, et al. Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease. Am J Med. 2004;117:925-931.
29. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880-887.
30. Bristow MR, Ginsburg R, Umans V, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986;59:297-309.
31. Persson B, Andersson OK, Hjemdahl P, Wysocki M, Agerwall S, Wallin G. Adrenaline infusion in man increases muscle sympathetic nerve activity and noradrenaline overflow to plasma. J Hypertens. 1989;7:747-756.
32. Arnold JM, McDevitt DG. Heart rate and blood pressure responses to intravenous boluses of isoprenaline in the presence of propranolol, practolol and atropine. Br J Clin Pharmacol. 1983;16:175-184.
33. Strauss MH, Reeves RA, Smith DL, Leenan FHH. The role of cardiac β1-receptors in the hemodynamic response to a β2-agonist. Clin Pharmacol Ther. 1986;40:108-115.
34. Levine MA, Leenen FH. Role of beta 1-receptors and vagal tone in cardiac inotropic and chronotropic responses to a beta 2-agonist in humans. Circulation. 1989;79:107-115.
35. Schäfers RF, Adler S, Daul A, et al. Positive inotropic effects of the β2-adrenoceptor agonist terbutaline in the failing human heart: effects of long-term β1-adrenoceptor antagonist treatment. J Am Coll Cardiol. 1994;23:1224-1233.
36. Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168-2174.
37. Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352:666-675.
38. Zhang Y, Bunjhoo H, Xiong W, Xu Y, Yang D. Association between C-reactive protein concentration and chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Int Med Res. 2012;40: 1629-1635.